Printed from Voxsanity (voxsanity.com.au) — NCT05924776 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 3 Ovarian Cancer Trial, Not Yet Recruiting
NCT05924776
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 to 80 years old (inclusive) who are female.
- People who have been diagnosed with ovarian cancer confirmed by a tissue sample (biopsy), can provide the pathology report, and whose cancer is classified as stage III or stage IV.
- People whose ovarian cancer has stopped responding to platinum-based chemotherapy (known as platinum-resistant), who have received at least one course of standard platinum-based chemotherapy as described in China's ovarian cancer treatment guidelines (2022), and whose cancer has been confirmed to be getting worse on scans.
- People whose cancer can be measured or tracked — either through at least one measurable area of cancer visible on imaging, or through a continuously rising tumour marker in blood tests, assessed using standard RECIST 1.1 criteria.
- People who do not plan to receive any other cancer treatments during the Plasmodium immunotherapy treatment period.
- People with an ECOG performance score of 0 or 1, meaning they are fully active or have only minor limitations in daily activity.
- People with an expected survival of at least 3 months.
- People whose blood test results meet certain minimum levels — without needing blood transfusions or blood-boosting medications in the 14 days before screening — including adequate levels of neutrophils, platelets, haemoglobin, red blood cell appearance, and albumin (confirm specific values with trial site).
- People who are able to become pregnant and agree to either abstain from sex or use effective contraception (such as an intrauterine device) from the time of signing the consent form until at least 24 weeks after completing Plasmodium immunotherapy treatment. (Note: people who have had surgical sterilisation or have not had a menstrual period for more than 24 cycles are considered to not have pregnancy potential.)
- People who are fully able to understand and sign the informed consent form.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have taken any experimental drug within 4 weeks before the first Plasmodium parasite treatment, or who are currently participating in another clinical trial that involves an active intervention (observational studies or those in follow-up only may be exceptions — confirm with trial site).
- People with immune system deficiency conditions, including HIV infection or other inherited or acquired immune deficiency diseases.
- People with blood clotting problems, or active or ongoing bleeding disorders.
- People who have had other cancer treatments that ended fewer than 14 days or fewer than 5 half-lives of that treatment before screening, whichever comes first.
- People who have had external or internal radiotherapy, where fewer than 28 days have passed between the end of radiotherapy and the start of this trial.
- People with serious haemoglobin disorders (haemoglobinopathies) or severe G6PD deficiency (a genetic enzyme deficiency affecting red blood cells).
- People who have had their spleen removed or who have an enlarged spleen.
- People with drug addiction or alcohol addiction.
- People with significant fluid build-up around the lungs, around the heart, or in the abdomen.
- People with active hepatitis B or hepatitis C infection.
- People with a significantly low count of a specific immune cell type (CD4+ T cells below 200 per microlitre), or who have received any form of immune-suppressing treatment within 28 days before the trial treatment.
- People with serious or uncontrolled conditions such as active infection, severe high blood pressure, unstable chest pain (angina), heart failure, serious heart disease, serious irregular heartbeat, liver or kidney problems, or previous heart attack, among others.
- People who currently have or have a history of a mental health disorder.
- People who have had major surgery within three months before the screening period.
- People who have previously received a bone marrow transplant or an organ transplant.
- People with moderate or severe lung ventilation problems.
- People who are currently receiving cancer treatment that is working or showing no clear signs of disease progression.
- People whom the trial investigator judges may not be able to tolerate the Plasmodium immunotherapy.
- People who are pregnant, breastfeeding, or who have been pregnant within 6 months after treatment.
- People who, in the investigator's judgement, have other conditions that make participation in the trial unsuitable.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Principal Investigator: Guo Shuiqun, Ph.D., M.D., The Third Affiliated Hospital of Southern Medical University
Phone: 86-13602467407
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.
Registry
ClinicalTrials.gov
Start date
20 July 2024
Est. completion
30 November 2026
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Objective response rate（ORR）; Progression-free survival (PFS); Disease control rate (DCR); 1-year survival rate; 2-year survival rate; Overall survival (OS); Tumor marker level
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.